Neoadjuvant systemic therapy for hepatocellular carcinoma
Surgical resection and liver transplant remain the only curative therapies for most patients
with hepatocellular carcinoma (HCC). Systemic therapy options have typically been …
with hepatocellular carcinoma (HCC). Systemic therapy options have typically been …
Evidence and Future Perspectives for Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Scoping Review
Y Endo, M Kitago, Y Kitagawa - Cancers, 2024 - mdpi.com
Simple Summary Pancreatic cancer presents a challenge due to its high mortality rates and
limited treatment options. In an effort to improve patient outcomes, neoadjuvant treatment …
limited treatment options. In an effort to improve patient outcomes, neoadjuvant treatment …
[HTML][HTML] Advancements in neoadjuvant immune checkpoint inhibitor therapy for locally advanced head and neck squamous Carcinoma: A narrative review
J Li, Z Luo, S Jiang, J Li - International Immunopharmacology, 2024 - Elsevier
The prevalent treatment paradigm for locally advanced head and neck squamous carcinoma
(HNSCC) typically entails surgery followed by adjuvant radiotherapy and chemotherapy …
(HNSCC) typically entails surgery followed by adjuvant radiotherapy and chemotherapy …
Safety and Efficacy Analysis of PD-1 Inhibitors in Combination with Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer: A Real-World, Single-Center …
Z Chen, Y He, C Ding, J Chen, Y Gu… - OncoTargets and …, 2023 - Taylor & Francis
Background Pancreatic cancer is a deadly disease with a low five years survival rate, and
chemotherapy remains the standard treatment for advanced cases. However, the efficacy of …
chemotherapy remains the standard treatment for advanced cases. However, the efficacy of …
[HTML][HTML] Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocarcinoma
SQ Zhou, P Wan, S Zhang, Y Ren, HT Li… - World Journal of …, 2024 - ncbi.nlm.nih.gov
BACKGROUND Pancreatic adenocarcinoma, a malignancy that arises in the cells of the
pancreas, is a devastating disease with unclear etiology and often poor prognosis. Locally …
pancreas, is a devastating disease with unclear etiology and often poor prognosis. Locally …
Molecular underpinnings of pancreatic cancer: Innovations in treatment and future perspectives
M Tez, E Sahingöz, F Martlı - Gastrointestinal Tract, 2023 - hksmp.com
This review would delve into the latest developments in the molecular landscape of
pancreatic cancer and how this knowledge can be applied to cancer treatments. It could …
pancreatic cancer and how this knowledge can be applied to cancer treatments. It could …
[HTML][HTML] Immunotherapy Perspectives for Pancreatic Ductal Adenocarcinoma (PDAC)
S Hajivalizadeh, S Akhondzadeh - Journal of Iranian Medical Council, 2024 - jimc.ir
Pancreatic cancer commonly refers to Pancreatic Ductal Adenocarcinoma (PDAC) which
accounts for more than 90% of pancreatic cancers (1). The substantial burden of disease is …
accounts for more than 90% of pancreatic cancers (1). The substantial burden of disease is …